How to get an ophthalmologist to sign off on an experimental drug
By Andrew MccollumRead moreThe ophthalmology unit at the University of Queensland has taken the unusual step of signing off on a new experimental drug.
The company, Aventis, is making the drug called Rheumatoid Arthritis Drug (RBD).
It is one of the first of its kind, and it has the potential to help thousands of people with rheumatology.
“It will allow us to test and validate our clinical trials and develop our clinical products and develop the clinical drug,” said Dr Daniel Lee, head of the ophthalmic unit at The University of Brisbane.
“I think we’re going to be able to see more people with this drug in a shorter period of time.”
The company is using a new technique called bioelectrical tomography (PET) to measure the levels of the drug in blood.
It is an optical technique that uses special high-powered microscopes to scan a sample of tissue and measure its surface properties.
Dr Lee said the technique had been proven successful in other cancer treatments, including the use of nanoparticles to deliver the drug.
“The potential of this new approach is that we can potentially test and evaluate these drugs in a lot more people,” he said.
“You might see this drug being tested in many people in a short period of times, which is really exciting.”
It is the first drug developed by the company and was developed by an Australian team led by Dr Jens Meyer.
“This drug, RBD, is the latest development in a long list of RBD drugs that we have been developing in Australia,” Dr Lee said.
It will be tested in patients who have arthritis and other joint problems, but it is hoped the drug will also be used to treat other diseases.
“We hope it will be useful in the treatment of osteoarthritis and other conditions like depression and anxiety,” Dr Meyer said.
Dr Meyer said the drug could be a huge boon for patients.
“If we have a drug that’s effective for arthritis, then we will be able more quickly and we can test the efficacy of this drug and test it in a larger number of people,” Dr Michael Meyer, professor of ophthalmoscope at the university, said.
Topics:cancer,health,health-policy,diseases-and-disorders,research,drs-andrews-courses,clinical-trials,dental-surgery,doses-and/or-doses,united-statesFirst posted February 13, 2019 09:40:58Contact Sarah CrouchMore stories from New South Wales